JPRN-UMIN000018382已完成1 期
Phase I study of neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel for patients with borderline resectable pancreatic cancer - NAC-GEMABR
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Severe drug hypersensitivity 2. Multiple primary cancers within 5 years 3. Severe infection 4. With grade2 or more severe peripheral neuropathy 5. With intestinal paralysys, ileus 6. Interstitial pneumonia or pulmonary 7. With uncontrollable pleural effusion or ascites 8. Receiving atazanavir sulfate 9. With uncontrollable diabetes 10.With uncontrollable heart failure, angina, hypertension, arrhythmia 11.With severe psychological symptoms 12.With watery diarrhea 13.Pregnant or lactating women, or women with known or suspected pregnancy 14.Inappropriate patients for entry on this study in the judgment of the investigator
研究者
相似试验
招募中
不适用
A Phase I study of adjuvant chemotherapy with gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomyBiliary tract cancer undergoing curative resection without major hepatectomyJPRN-UMIN000007454Kansai Hepatobiliary Oncology Group (KHBO)24
已完成
不适用
A Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomyBiliary tract cancer undergoing curative resection without major hepatectomyJPRN-UMIN000004622Kansai Hepatobiliary Oncology Group (KHBO)24
已完成
不适用
Phase II study of adjuvant chemotherapy with gemcitabine and regional arterial infusion of nafamostat mesilate for the patients with resectable pancreatic cancerJPRN-UMIN000006163Jikei University school of Medicine30
已完成
不适用
Phase II study of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy with S-1 in patients with locally advanced pancreatic cancerlocally advanced pancreatic cancerJPRN-UMIN000006332Chiba Cancer Center30
已完成
2 期
Phase II study of Neoadjuvant chemotherapy with Gemcitabine and S1 (GS therapy) for resectable pancreatic carcinoma (NAC GS2+2)resectable pancreatic cancerJPRN-UMIN000009070EXTSURG35